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Preparation and culture of precision-cut liver slices (PCLS)
Studies
 Liver procurement
2. Preparation of PCLS
3. Number of PCLS
• Rat liver: 200-250 (5 mm)
• Mouse liver: 40-50 (5 mm)
4. Culture systems
• Submerged systems (well plates)
• Dynamic organ culture system 5. Culture of PCLS
• 12 well plates
• William Medium E supplemented 
with 25 mM glucose and 
50 μg/ml gentamycin
• Under 95% O2/5% CO2
• At 37 ºC
Future avenues
Further validation of PCLS is necessary, by directly comparing in vivo and ex 
vivo studies, preferably in the same experimental setting, to show the predictive 
power of PCLS for liver pathology and pharmacological intervention in vivo. 
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le 1. Studies performed in PCLS. Sp, species;  h, human; r, rat; HSP47, heat-shock protein 47; Col1A1, collagen 1α(I); Pcol1A1, procollagen 1α(I)/mRNA; HYP, hydroxyproline; M6P-HSA, mannose-6-phos-
te-human serum albumin; CAR, constitutive androstane receptor; AhR, aryl hydrocarbon receptor; PXR, pregnane X receptor; NTCP, Na+-taurocholate co-transporting polypeptide; MRP2, multidrug resistance 
ociated protein 2.
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   To improve and accelerate drug discovery, there is an urgent need for 
reliable and reproducible (animal and especially human) in vitro meth-
ods to test compounds for the treatment of liver diseases, such as viral 
hepatitis, NASH, fibrosis, and hepatocellular carcinoma. The in vitro
models currently utilized in liver research cannot predict or mimic the 
complex cellular interactions that occur in vivo. Thus in isolated primary 
cells or cell lines, dedifferentiation rapidly occurs, partly due to the loss 
of the natural environment, including cues from the extracellular matrix 
and neighbouring or migratory cells. On the other hand, utilization of in 
vivo animal experiments has other shortcomings. In vivo studies (1) re-
quire large numbers of animals for extended time periods, raising both
ethical and financial issues, (2) suffer from interindividual variation, and
(3) also have limited implications for human disease, not only due to 
the notorious lack of appropriate models, but also to relevant species
differences in molecular pathogenesis [1]. Therefore, ex vivo models
are needed that (1) resemble the in vivo environment, (2) are reproduc-
ible, (3) are low cost and reduce the requirement of live animals, and
(4) permit the testing in complex human systems. Precision-cut tissue 
slices (PCLS) represent an ex vivo tissue culture technique that mimics
the multicellular characteristics of organs in vivo.
  Ex vivo liver research started with the pioneering work of Warburg and 
Krebs in the early twenties [2]. They used liver slices that were prepared 
manually with limited reproducibility and viability. After a decline in fa-
vour of in vitro techniques and of another ex vivo (liver perfusion) model, 
the principle was resurrected in the nineties, when the Krumdieck slicer 
was developed, enabling the production of reproducible and viable tis-
sue slices. In addition, different incubation systems were developed to 
successfully culture PCLS [3,4], maintaining viability of hepatocytes, 
Kupffer, endothelial, and hepatic stellate cells [1,5]. Drug transport stud-
ies in PCLS clearly showed that besides small molecules, such as di-
goxin, also larger molecules, like modified human serum albumin, can 
enter PCLS [6]. De Graaf et al. [7] published a detailed description of 
the preparation and culture of PCLS (see Figure). Another emerging ex 
vivo technique is the decellularized liver extracellular matrix [8]. Com-
pared to the multicellular PCLS that contain a native extracellular matrix 
(ECM), it uses an altered ECM and is a complex technique. Moreover, 
to date only single cell types have been used to repopulate these ECM 
scaffolds.
Current use
PCLS have been used extensively to examine drug metabolism and 
toxicity. Several studies showed the relevance of PCLS in predicting 
drug metabolism in the human body [1]. Extrapolations from the results
obtained in PCLS to the in vivo condition have been successfully es-
tablished for metabolic clearance, metabolism, and toxicity of several
drugs (Table 1). This can be explained by a relatively stable expression 
of transporters and enzymes that are involved in drug metabolism dur-
ing culture of PCLS [9]. However, others found decreased expression
of certain iso-enzymes and drug transporters (Table 1), which was at-
tributed to the lack of endogenous or exogenous inductive stimuli in 
PCLS culture medium [9], a problem which needs to be addressed in 
future studies.
   Taking advantage of the multicellular composition of PCLS, different 
stages of (human) liver fibrosis have been successfully investigated, 
not only to study mechanisms of fibrogenesis, but also to assess the 
efficacy of anti-fibrotic agents, using, e.g., the downregulation of procol-
lagen type I gene and protein expression as readout [5,10].
   Studies on hepatitis B and C are impeded by their limitation to cell 
culture and complex in vivo disease models. A recent report has dem-
onstrated the feasibility of hepatitis C studies in human PCLS [11].
Furthermore, PCLS are now also used in cancer and metabolic liver 
disease research [12,13].
Future avenues
   Further validation of PCLS is necessary, by directly comparing in 
vivo and ex vivo studies, preferably in the same experimental setting, to 
show the predictive power of PCLS for liver pathology and pharmaco-
logical intervention in vivo.
   Furthermore, PCLS could become an important tool for a personalized
medicine. Thus PCLS can be prepared from resected tumor material
[12], to determine the most effective cytostatic drug or drug combination
ex vivo. Precision-cut slices can also be prepared and maintained from 
other organs [3] enabling serial multi-organ incubations, allowing, e.g., 
studies on the gut-liver axis [14].
   Human PCLS can be cultured for up to 7 days [15], but some functions, 
such as full metabolic capacity, are maintained only for 3 days (Table 
Journal of Hepatology 2013 vol 1) [15]. Therefore, PCLS culture conditions should be further optimized 
to better model the liver in vivo over prolonged periods of time. Using 
exogenous and endogenous inductive stimuli and adding circulating 
components, e.g., lymphocytes, innate immune cells, chemokines or 
hormones, could improve the reliability of PCLS. Further progress is 
also envisaged by perifusing PCLS in a microfluidic system [14]. PCLS 
are not yet an established tool in drug discovery, likely due to the ab-
sence of PCLS cryo-banks that would facilitate material exchange and 
standardization. Such cryopreservation appears indeed feasible [16].
Conclusion
In summary, PCLS are a unique and promising ex vivo system, located
in-between experimental and human studies. This technology promises
to develop into a pivotal tool to assess hepatic drug metabolism and 
toxicology, and to test pharmacological agents in various liver diseases.
© 2013  European Association for the Study of the Liver. Published 
by Elsevier B.V. All rights reserved.
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